| GTO ID | GTC2399 |
| Trial ID | NCT04464889 |
| Disease | Multiple Myeloma | Malignant Lymphoma | Leukemia | Myelodysplastic Syndrome | Myelofibrosis |
| Altered gene | HA-1H |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | MDG1021 |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | A Dose-Escalation, Open Label Phase I Study to Assess the Safety, Feasibility and Preliminary Efficacy of HA-1H TCR Modified T Cells, MDG1021, in Patients With Relapsed or Persistent Hematologic Malignancies After Allogeneic HSCT With or Without Unmanipulated DLI |
| Year | 2020 |
| Country | Netherlands |
| Company sponsor | Medigene AG |
| Other ID(s) | CD-TCR-003 |
| Cohort1: dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: dose level 2 | |||||||||||
|
|||||||||||
| Cohort3: dose level 3 | |||||||||||
|
|||||||||||